Pilot Projects Program

总结 临床和转化基础设施网络（CTR-IN）是由7个州的13个机构组成的合作伙伴关系 发展合作的多学科临床和转化健康差异研究的文化， 和整个西部IDEA机构，以积极影响我们社区的健康。支持CTR试点 项目是关键的CTR-IN活动之一。CTR-IN试点项目计划（CP 3，以前称为CTPG [临床和转化试点赠款]）已经制定了经过充分测试的征集、择优评审和 监督试点赠款。CTR-IN试点获奖者的成功是通过紧密集成 CP 3为研究者提供生物统计、指导和专业发展支持， 互补的CTR-IN核心。为了进一步发展成功的CP 3，我们已经发展了我们的战略， 健康差异研究，我们已经制定了创新战略，以支持多站点合作 建立多学科的CTR团队。国家方案3的供资战略将加强目前的合作减少风险能力 在该地区的几个方面。首先，在过去5年中，具有CTR-IN试点的调查员比例很高 赠款支持成功地获得了竞争性的校外资金，产生了积极的投资回报 会继续增长我们会继续与 新的社区参与和外展（CEO）核心，以确定风险人群和健康差异， 关注我们的社区。其次，跨站点合作将建立必要的基础设施， 在全国范围内进行多中心临床试验和相关研究。我们最近支持多站点协作试点 项目表明了研究人员对此类项目的需求以及 启动这些更复杂的项目。最后，支持连接临床前和临床的伙伴关系 研究将加速向患者和社区提供解决方案。我们合作机构的教师 包括由IDeg支持的基础科学、临床前研究者（例如，INBRE、COBRE）和 临床研究者，为建立团队和利用核心资源推进 为患者和社区带来更大的利益。总之，这些战略和预期成果 将对我们社区的健康产生重要影响。

Summary The Clinical and Translational Infrastructure Network (CTR-IN) is a partnership of 13 institutions across 7 states to develop a culture of collaborative multidisciplinary clinical and translational health disparities research within and across western IDeA institutions to positively impact health in our communities. Support for CTR pilot projects is one of the key CTR-IN activities. The CTR-IN Pilot Projects Program (CP3, formerly known as CTPG [Clinical and Translational Pilot Grants]) has developed well-tested strategies for solicitation, merit review, and oversight of pilot grants. The success of CTR-IN pilot awardees is made possible through the close integration of CP3 funding for investigators with the biostatistical, mentorship and professional development support from the complementary CTR-IN Cores. To further grow the successful CP3, we have evolved our strategy to focus on health disparities research, and we have developed innovative strategies to support multisite collaborations and the building of multidisciplinary CTR teams. The CP3 funding strategies will enhance current CTR capacity in the region on several fronts. First, over the past 5 years a high proportion of investigators with CTR-IN pilot grant support have successfully obtained competitive extramural funding, yielding a positive return on investment that will continue to grow. We will continue to advance this objective by working in close collaboration with the new Community Engagement and Outreach (CEO) Core to identify populations at risk and health disparities of concern in our communities. Second, partnering across sites will build the necessary infrastructure to compete nationally for multisite clinical trials and related research. Our recent support of multisite collaborative pilot projects demonstrates both the demand for such projects among researchers and the proof of concept for initiating these more complex projects. Finally, supporting partnerships that bridge preclinical and clinical research will accelerate the delivery of solutions to patients and communities. Faculty at our partner institutions include a broad cohort of IDeA-supported basic science, preclinical investigators (e.g., INBRE, COBRE) and clinical investigators, yielding opportunities for building teams and leveraging core resources to advance research for greater benefit to patients and communities. Altogether, these strategies and anticipated outcomes will have an important impact on health in our communities.